Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Published Time:
2024-10-28 17:53
Source:
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
This program targets high-tech enterprises, selecting high-growth sci-tech enterprises with sound governance, focused core businesses, strong competitiveness, and development potential. Its goal is to facilitate financing channels for high-tech enterprises and connect them with multi-level capital markets. Jiangsu Vcare's inclusion reflects the Provincial Department of Science and Technology's recognition of its comprehensive development potential and technological innovation. The company will continue focusing on its core responsibilities to accelerate its listing process.
As aNational "Little Giant" Enterprise, Jiangsu Vcare has specialized in innovative drugs and advanced therapies for 14 years, operating under a group management model with a high-quality R&D and production team of nearly 1,000. It currently has5 clinical-stage Class I innovative drug projectsand over10 preclinical projects, featuring a pipeline centered on the anti-platelet drug Vicagrel,covering therapeutic areas including cardiovascular, oncology, and autoimmune diseases.
With support from this program, Jiangsu Vcare will advance steadily toward listing, enhancing its core competitiveness to contribute to Jiangsu's and China’s technological and economic progress.
Related News
01
2023
/
11
Recently, the pivotal Phase II clinical study for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 for treating NTRK fusion-positive solid tumors was approved by the NMPA. This clinical study will further evaluate the efficacy and safety of VC004 in patients with NTRK fusion mutations. Upon success, Jiangsu Vcare plans to submit an NDA in China.
View Details
11
2023
/
08
Recently, the second-generation selective JAK1 inhibitor VC005 Topical Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first topical skin dosing in a patient with mild-to-moderate atopic dermatitis（AD）.
View Details
21
2023
/
07
Recently, the second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), completed the first patient dosing in its Phase II clinical trial for moderate-to-severe atopic dermatitis (AD).
View Details
11
2023
/
07
Jiangsu Vcare Awarded "Jiangsu Provincial Science and Technology Award (Second Prize)"
In July, the Jiangsu Provincial Government announced the recipients of the 2022 Jiangsu Provincial Science and Technology Awards. Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), as a participating unit, jointly completed the project New Pharmaceutical Cocrystal Technology and Its Industrial Application with the research team of Zhang Jianjun and Gao Yuan from China Pharmaceutical University.
View Details
04
2023
/
05
The second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), recently initiated its Phase II clinical study for ankylosing spondylitis (AS). On April 26th, the first patient was successfully dosed at Peking University People's Hospital. VC005 Tablet demonstrated favorable metabolic properties, safety, and tolerability in the completed Phase I clinical study.
View Details
21
2023
/
03
Recently, the second-generation selective JAK1 inhibitor VC005 Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received approval from the NMPAto conduct clinical trials. The target indication is mild-to-moderate atopic dermatitis (AD). Related Phase I clinical trial work is scheduled to commence shortly.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn